ReviewNeuropsychopharmacology reports2020
PET technology for drug development in psychiatry.
Review in Neuropsychopharmacology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Neuroimaging as a Tool for Advancing Pediatric Psychopharmacology.Paediatric drugs · 2025Review
- Experimental Medicine Approaches in Early-Phase CNS Drug Development.Advances in neurobiology · 2023Article
- Production of [Molecules (Basel, Switzerland) · 2022Article
- Evaluation of (Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Novel drug developmental strategies for treatment-resistant depression.British journal of pharmacology · 2022Review
- Performance evaluation of the IRIS XL-220 PET/CT system, a new camera dedicated to non-human primates.EJNMMI physics · 2022Article
- Effect of DL-Methylephedrine on Dopamine Transporter Using Positron Emission Tomography With [Frontiers in psychiatry · 2022Article
- Prospects for improved prevention and treatment of neuropsychiatric disorders:Neuroscience applied · 2022Article
- Molecular imaging of the serotonin transporter availability and occupancy by antidepressant treatment in late-life depression.Neuropharmacology · 2021Article
- Interaction of Ligands for PET with the Dopamine D3 Receptor: In Silico and In Vitro Methods.Biomolecules · 2021Article
- PET technology for drug development in psychiatry.Neuropsychopharmacology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron emission tomography (PET) is a non-invasive imaging method to measure the molecule in vivo. PET imaging can evaluate the central nervous system drugs as target engagement in the human brain. For antipsychotic drugs, adequate dopamine D2 receptor occupancy ("therapeutic window") is reported to be from 65%-70% to 80% to achieve the antipsychotic effect without extrapyramidal symptoms. For antidepressants, the clinical threshold of serotonin transporter (5-HTT) occupancy is reported to be 70%-80% although the relation between the side effect and 5-HTT occupancy has not yet been established. Evaluation of norepinephrine transporter (NET) occupancy for antidepressant is ongoing as adequate PET radioligands for NET were developed recently. Measurement of the target occupancy has been a key element to evaluate the in vivo target engagement of the drugs. In order to evaluate new drug targets for disease conditions such as negative symptoms/cognitive impairment of schizophrenia and treatment-resistant depression, new PET radioligands need to be developed concurrently with the drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.